We provide you with 20 years of free, institutional-grade data for PLX stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of PLX. Explore the full financial landscape of PLX stock.
| Reported Date | CIK | Ticker | Type |
|---|
Protalix BioTherapeutics, Inc(NYSE MKT:PLX) 
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, rest of Latin America, and internationally. The company o...
Website: http://www.protalix.com
Founded: 1993
Full Time Employees: 196
CEO: Dror Bashan
Sector: Healthcare
Industry: Biotechnology
The information provided in this report about PLX stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.